The UAE has approved the emergency use of Sinopharm CNBG vaccine.
According to the Ministry of Health and Prevention (MoHAP) it approved the emergency use of the Sinopharm CNBG’s new recombinant protein vaccine which it said was in “full compliance with the regulations and laws for a faster review of licencing procedures.”
RELATED STORY: Over 45 million Filipinos fully vaccinated against COVID-19
This is to enhance the prevention of community members from the COVID-19 pandemic.
This followed study on individuals who were previously vaccinated with two doses of the Sinopharm CNBG’s inactivated vaccine and the seroconversion rate was up to 100% of neutralising antibodies, along with high safety rates and no side effects among all the participants.
READ ON: Emirates SkyCargo delivers 600m doses of COVID-19 vaccines
The vaccine demonstrated an improved immune capacity against the SARS-CoV-2 variants.
The new vaccine will be produced and distributed by Hayat Biotech, a JV between G42 and Sinopharm CNBG. The vaccine will be available to the public as a booster dose starting January 2022. (AW)
